TP53 mutations associate with higher in vitro resistance of CLL cells to ofatumumab and rituximab
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Related projects: |
| Authors | |
|---|---|
| Year of publication | 2013 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Related projects: |